Deals this week: Intec Pharma, FIMECS, Mereo Biopharma Group

13th April 2018 (Last Updated August 12th, 2019 10:39)

Israeli drug development company Intec Pharma Ltd has issued an underwritten public offering of shares of its common stock.

Israeli drug development company Intec Pharma Ltd has issued an underwritten public offering of shares of its common stock.

Underwriters will be granted a 30-day option to buy an additional 15% shares.

Intec Pharma plans to use proceeds to finance phase three development of Accordion Pill Carbidopa/Levodopa. It will also use funds for pre-commercial activities and other general corporate purposes.

The company has appointed Oppenheimer & Co as sole book-running manager, and Meitar Liquornik Geva Leshem Tal and Greenberg Traurig LLP as legal advisors for the transaction.

Japanese biotechnology company FIMECS, Inc has raised ‎$2.34m in a seed financing round led by Cosmo Bio Co Ltd.

The company has simultaneously entered a licensing agreement with Takeda Pharma for the development of immuno-oncology therapies.

UK-based biopharmaceutical company Mereo Biopharma Group Plc plans to issue 113 million ordinary shares in the form of ADRs through a global public offering.

The company simultaneously plans to issue 45 million ordinary shares outside the US and Canada in a private placement.

Mereo Biopharma Group plans to use the proceeds for clinical development of BPS-804 for the treatment of OI in adults and children, and clinical development of AZD-9668 for the treatment of severe AATD, as well as for the commercialisation of BCT-197.

The company has appointed Cowen and Company, LLC, BMO Capital Markets Corp and RBC Capital Markets LLC as book-running managers for the transaction and Latham & Watkins LLP as legal advisor.

US-based Surface Oncology Inc has issued six million shares of its stock priced between $13 and $15 a share to raise proceeds ranging from $78m to $90m.

The company plans to use the proceeds for conducting phase one clinical trial on SRF231, and to continue the ongoing research and development of its product candidates and additional programmes.

"The company simultaneously plans to issue 45 million ordinary shares outside the US and Canada in a private placement."

The company has appointed Goldman Sachs & Co LLC, Cowen and Company LLC, and Evercore Group LLC as joint bookrunners, and Goodwin Procter LLP as legal advisor for the transaction.

US-based Constellation Pharmaceuticals Inc has raised $100m in financing.

A group of investors including Cormorant Asset Management, Deerfield Management, Fidelity Management and Research Company, Hillhouse Capital, NS Investment, OrbiMed, Venrock Healthcare Partners, and Sirona Capital provided the financing.

Current investors also participating in the financing round included The Column Group, Third Rock Ventures, Venrock, SROne, University of California Investment Office, Topspin Partners, and Casdin Capital.

Constellation Pharmaceuticals plans to use the proceeds for conducting multiple clinical trials across its portfolio.

Japanese biopharmaceutical products provider NanoCarrier Co Ltd issued 1.5 million shares priced at ‎$7.54 a share in a private placement to raise ‎$11.3m.

Noritsu Koki Co Ltd, a photo processing machine manufacturer also based in Japan, will subscribe to the placement and purchase 3.47% share in NanoCarrier.

Indian active pharmaceutical ingredients (APIs) producer Neuland Laboratories Ltd plans to issue 1.6 million securities in a private placement.

Qualified institutional investors will subscribe to the placement.

The company will issue securities such as equity shares, warrants or convertible securities through a preferential issue as part of the transaction.

The company plans to use the proceeds for repayment of debt, for business growth, and to strengthen its balance sheet.

Chinese biotechnology company Beijing Biocytogen Co Ltd has raised $65m in a series C financing round led by CMB International Capital Corporation Limited.

The funding round also saw the participation of SDIC Venture Capital Management, 3E Bioventures Capital, Cowin Capital Group and Suzhou Oriza Holdings Co Ltd.

US-based life science-focused investment firm Casdin Capital LLC has agreed to invest in BioLife Solutions Inc.

Casdin Capital has agreed to buy one million shares of BioLife Solutions in a private transaction from its ssecond-biggest shareholder as part of a private transaction.

Based in the US, BioLife Solutions is a developer, manufacturer and marketer of proprietary clinical-grade biopreservation media.